Crown J - Search Results

1

Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer.

Gaynor N, Crown J, Collins DM. Gaynor N, et al. Among authors: crown j. Semin Cancer Biol. 2022 Feb;79:44-57. doi: 10.1016/j.semcancer.2020.06.016. Epub 2020 Jul 2. Semin Cancer Biol. 2022. PMID: 32623044 Free article. Review.

2

EGFR and HER-2 antagonists in breast cancer.

O'Donovan N, Crown J. O'Donovan N, et al. Among authors: crown j. Anticancer Res. 2007 May-Jun;27(3A):1285-94. Anticancer Res. 2007. PMID: 17593621 Free article. Review.

3

Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells.

O'Donovan N, Byrne AT, O'Connor AE, McGee S, Gallagher WM, Crown J. O'Donovan N, et al. Among authors: crown j. Invest New Drugs. 2011 Oct;29(5):752-9. doi: 10.1007/s10637-010-9415-5. Epub 2010 Mar 16. Invest New Drugs. 2011. PMID: 20229355

4

Targeted therapy for triple-negative breast cancer: where are we?

Duffy MJ, McGowan PM, Crown J. Duffy MJ, et al. Among authors: crown j. Int J Cancer. 2012 Dec 1;131(11):2471-7. doi: 10.1002/ijc.27632. Epub 2012 Jun 7. Int J Cancer. 2012. PMID: 22581656 Free article. Review.

5

Gene expression changes as markers of early lapatinib response in a panel of breast cancer cell lines.

O'Neill F, Madden SF, Aherne ST, Clynes M, Crown J, Doolan P, O'Connor R. O'Neill F, et al. Among authors: crown j. Mol Cancer. 2012 Jun 18;11:41. doi: 10.1186/1476-4598-11-41. Mol Cancer. 2012. PMID: 22709873 Free PMC article.

6

Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines.

Pierce A, McGowan PM, Cotter M, Mullooly M, O'Donovan N, Rani S, O'Driscoll L, Crown J, Duffy MJ. Pierce A, et al. Among authors: crown j. Cancer Biol Ther. 2013 Jun;14(6):537-45. doi: 10.4161/cbt.24349. Cancer Biol Ther. 2013. PMID: 23760496 Free PMC article.

7

A gene expression profile indicative of early stage HER2 targeted therapy response.

O'Neill F, Madden SF, Clynes M, Crown J, Doolan P, Aherne ST, O'Connor R. O'Neill F, et al. Among authors: crown j. Mol Cancer. 2013 Jul 1;12:69. doi: 10.1186/1476-4598-12-69. Mol Cancer. 2013. PMID: 23816254 Free PMC article.

8

Neuromedin U: a candidate biomarker and therapeutic target to predict and overcome resistance to HER-tyrosine kinase inhibitors.

Rani S, Corcoran C, Shiels L, Germano S, Breslin S, Madden S, McDermott MS, Browne BC, O'Donovan N, Crown J, Gogarty M, Byrne AT, O'Driscoll L. Rani S, et al. Among authors: crown j. Cancer Res. 2014 Jul 15;74(14):3821-33. doi: 10.1158/0008-5472.CAN-13-2053. Epub 2014 May 29. Cancer Res. 2014. PMID: 24876102

9

PP2A inhibition overcomes acquired resistance to HER2 targeted therapy.

McDermott MS, Browne BC, Conlon NT, O'Brien NA, Slamon DJ, Henry M, Meleady P, Clynes M, Dowling P, Crown J, O'Donovan N. McDermott MS, et al. Among authors: crown j. Mol Cancer. 2014 Jun 24;13:157. doi: 10.1186/1476-4598-13-157. Mol Cancer. 2014. PMID: 24958351 Free PMC article.

10

cMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients?

Gaule PB, Crown J, O'Donovan N, Duffy MJ. Gaule PB, et al. Among authors: crown j. Expert Opin Ther Targets. 2014 Sep;18(9):999-1009. doi: 10.1517/14728222.2014.938050. Epub 2014 Aug 1. Expert Opin Ther Targets. 2014. PMID: 25084805 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

359 results

Search Page